Skip to main content

Oncology Code Systems

HER2MethodCS

Description TBD

Code Display
single HER2 by Single Probe Assay In SituHybridization test
dual HER2 by Dual Probe Assay In SituHybridization test
ihc HER2 by ImmunoHistochemistry

DegreeOfLymphaticInvolvementCS

Description TBD

Code Display
microscopic Only a few cancer cells are in the node.
gross The cancer can be seen or felt without aid of microscopy.
extracapsular Cancer has pread outside the wall of the node.

DecileCS

Division of percentages into 10% intervals.

Code Display
0_10 0 to 10%
11_20 11 to 20%
21_30 21 to 30%
31_40 31 to 40%
41_50 41 to 50%
51_60 51 to 60%
61_70 61 to 70%
71_80 71 to 80%
81_90 81 to 90%
91_100 91 to 100%

StagingMethodCS

The methodology or standard used to do the staging.

Code Display
ajcc_v7 AJCC Breast Carcinoma Version 7
ajcc_v8 AJCC Breast Carcinoma Version 8

StagingTimeCS

When staging was done, relative to treatment events.

Code Display
clinical On initial diagnosis
pathologic Post-operative, after resection surgery
enrollment When patient is enrolled in a clinical trial
recurrence Upon recurrence of disease

BrcaReceptorStatusCS

Classification of receptor status in breast cancer.

Code Display
luminal_A Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy.
luminal_B Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2.
HER2_positive Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2.
Triple_negative Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy.